Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

PURPOSE: Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors (IMTs). We assessed the activity of the ALK inhibitor crizotinib in patients who had no known curative treatment options at d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Mossé, Yael P., Voss, Stephan D., Lim, Megan S., Rolland, Delphine, Minard, Charles G., Fox, Elizabeth, Adamson, Peter, Wilner, Keith, Blaney, Susan M., Weigel, Brenda J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5617123/
https://ncbi.nlm.nih.gov/pubmed/28787259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.4830
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados